ArticleSchizophrenia (Heidelberg, Germany)2025
Abnormal eye movement, brain regional homogeneity in schizophrenia and clinical high-risk individuals and their associated gene expression profiles.
Article in Schizophrenia (Heidelberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Eye Movement Patterns as Robust Biomarkers for Schizophrenia Identification Using a Novel Data Transformation Approach.Journal of eye movement research · 2026Article
- Recent developments in imaging transcriptomics for psychiatric disorders.Psychoradiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Clinical high-risk (CHR) is a prodromal period before psychosis characterized by attenuated, transient, or intermittent psychotic symptoms and declining functioning. They exhibit eye movement abnormalities and brain functional damage compared with schizophrenia, potentially increasing vulnerability to psychosis. This study investigates eye movement dysfunction and brain activity alterations in CHR and first-episode schizophrenia (FSZ) individuals to identify early biomarkers for psychosis progression. Twenty-seven drug-naïve FSZ, 25 CHR, and 28 healthy controls (HCs) were recruited for eye-tracking tasks and resting-state functional magnetic resonance imaging to evaluate eye movement and regional homogeneity (ReHo) differences. Machine-learning algorithms were used to differentiate FSZ from CHR. In combination with the Allen Human Brain Atlas (AHBA), transcriptome-neuroimaging analysis was applied to identify ReHo-related gene expression profiles. FSZ exhibited a wide range of eye movement abnormalities across multiple tasks, while certain abnormalities were already present in CHR. Abnormal ReHo alterations were found in orbitofrontal gyrus, temporal gyrus, and cingulum among three groups, associated with specific eye movement parameters. These differences in eye movement and ReHo allowed for high-accuracy discrimination between them. Genetic analysis identified significant genes in FSZ and CHR, enriched in various biological functions and pathways (all corrected p < 0.05). FSZ and CHR exhibited different eye movement and ReHo patterns, indicating potential as early biomarkers. Our findings reveal correlations between these ReHo patterns and gene expression profiles using AHBA database, shedding light on possible genetic mechanisms underlying brain function in FSZ and CHR.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.